Breakthrough Clinical Results
EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights include Phase 3 MANEUVER data for pimicotinib in tenosynovial giant cell tumor (TGCT), showing significant improvements in objective response rate and key secondary endpoints. Data for the antibody-drug conjugate (ADC) precemtabart tocentecan demonstrated encouraging efficacy in colorectal cancer (CRC), supporting further development. Additional data reinforced the benefit of BAVENCIO (avelumab) in first-line maintenance treatment for advanced bladder cancer.
Key Highlights
- Phase 3 MANEUVER data for pimicotinib in TGCT showed significant improvement in objective response rate and key secondary endpoints.
- Encouraging efficacy data for precemtabart tocentecan in colorectal cancer (CRC) supports further development.
- Data reinforced the benefit of BAVENCIO in first-line maintenance treatment for advanced bladder cancer.
- Presentations covered over 12 tumor types.
Incidence and Prevalence
Based on the provided context, there is no information available about the latest global estimates of incidence and prevalence of Tenosynovial giant cell tumor according to PubMed data. The context indicates that while some sources describe TGCT as a rare condition, specific global statistics on incidence and prevalence are not present in the provided information.
The context mentions some limited data points, such as one study identifying 4,664 patients with TGCT (284 with GCT-TS and 4,380 with PVNS) from health plan data, but this represents only a specific population and timeframe rather than global estimates. Similarly, another study noted that tumors of the foot and ankle represented 5.75% of all tumors treated by a single surgeon over 20 years, but this cannot be extrapolated to global prevalence.
The available information in the context focuses on other aspects of TGCT, including clinical characteristics, surgical treatments, gender and anatomical distribution, healthcare resource utilization, and clinical trials, but does not provide the specific global epidemiological data requested.
Economic Burden
Economic Burden of Treating Tenosynovial Giant Cell Tumor in the USA
A retrospective cohort study analyzed administrative claims for adult commercial and Medicare Advantage health plan enrollees with evidence of GCT-TS and PVNS (types of TGCT) from January 1, 2006 through March 31, 2015 in the USA. The study identified 4,664 patients with TGCT, including 284 with GCT-TS and 4,380 with PVNS.
Healthcare Costs
The study revealed that mean total healthcare costs increased significantly from preindex to postindex periods:
- For GCT-TS: From $8,943 to $14,880 (P < 0.001)
- For PVNS: From $13,221 to $17,728 (P < 0.001)
Ambulatory Costs
Ambulatory costs showed substantial increases:
- For GCT-TS: Nearly 120% increase from $4,340 to $9,570 (P < 0.001)
- For PVNS: 50% increase from $6,782 to $10,278 (P < 0.001)
More than half of the costs covered ambulatory care.
Treatment Utilization
Physical therapy use increased significantly:
- For GCT-TS: From 18% to 40% (P < 0.001)
- For PVNS: From 38% to 60% (P < 0.001)
Most patients with GCT-TS (78.2%) had at least one postindex surgery, compared with 38.7% of patients with PVNS.
These results suggest a high healthcare burden once TGCT is identified in the USA healthcare system.
Drug used in other indications
The context provided is "NA", which means there is no information available to answer the queries about pimicotinib's trial indications beyond Tenosynovial giant cell tumor or the intervention models for these trials. Without specific context information, I cannot provide any details about pimicotinib's clinical trials.